New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 27, 2012
10:34 EDTACADAcadia jumps over 150% following positive trial results
Acadia Pharmaceuticals surged over 150% in mid-morning trading after the company said its Pimavanserin drug for Parkinson's disease succeeded in meeting the primary goal and key secondary goals of a Phase III trial. In the study, which evaluated the efficacy, tolerability and safety of Pimavanserin in patients with Parkinson's disease psychosis, or PDP, Acadia said Pimavanserin met the primary endpoint of the trial by demonstrating highly significant antipsychotic efficacy as measured using the 9-item SAPS-PD scale. In addition, the drug met the secondary endpoint for motoric tolerability and clinical benefits were observed in all exploratory efficacy measures with significant improvements in nighttime sleep, daytime wakefulness and caregiver burden. Roger G. Mills, M.D., Acadia's EVP of Development, commented that "benefits of Pimavanserin were seen by patients, caregivers and investigators, as well as the independent raters." Acadia said it will continue ongoing preparations for a confirmatory Phase III trial, which will use the same design. Acadia is trading up $3.54, or 153.48%, to $5.82 in mid-morning trading.
News For ACAD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 3, 2015
09:40 EDTACADACADIA U.S. introduction of Nuplazid likely in 2016, says Ladenburg
Subscribe for More Information
07:04 EDTACADACADIA submits NDA for Nuplazid for treatment of Parkinson's Disease psychosis
Subscribe for More Information
07:04 EDTACADACADIA names Steve Davis president, CEO
ACADIA Pharmaceuticals announced that its Board of Directors has appointed Steve Davis as President and CEO. Davis has been serving as ACADIA's Interim Chief Executive Officer since March 2015. Davis has also been appointed to the ACADIA Board of Directors.
August 27, 2015
10:00 EDTACADOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
06:37 EDTACADACADIA upgraded to Overweight from Neutral at Piper Jaffray
Subscribe for More Information
August 25, 2015
09:59 EDTACADOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:07 EDTACADACADIA initiated with a Buy at Aegis
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use